Tag: R-Pharm

R-Pharm is a Russian private hi-tech pharmaceutical company founded in 2001, employs over 3500 highly qualified specialists, has over 60 branches. Turnover reached over $ 1,5 billion in 2013. R-Pharm operates in Russia and CIS, USA, Germany, Japan and India. The company is involved in R&D, manufacturing, marketing, sales and distribution of innovative pharmaceutical products from a broad number of therapeutic areas in specialty/hospital care. The company has operational GMP compliant manufacturing sites at Yaroslavl, Kostroma region and Germany and Novosibirsk/ R-Pharm is building a modern facility for the synthesis of active pharmaceutical ingredients in Rostov – Pharmoslavl. It is expected that the first phase of Pharmoslavl site will be put into operation in the end of 2016. The new facility will comply with the highest requirements of environmental and occupational safety and health standards for the workplace.

Over the time of operation of its manufacturing facilities the company has successfully passed audits and evaluation visits from the largest Global Pharma companies, such as Abbvie, Amgen, Astellas, AstraZeneca, BMS, Boryung, Dr.Reddy’s, Eli Lilly, Ferring, Glaxo Smith Kline, Johnson& Johnson, Mallinckrodt, MSD, Pfizer, Roche, and Sanofi. The R-Pharm’s facilities in the Yaroslavl and Kostroma regions implement dozens of complex advanced production technologies, which haven’t been used previously in the Russian Federation.

R-Pharm has invested in the establishment of biopharmaceutical products manufacturing facility based on FlexFactory processing line from the U.S. company Xcellerex. This facility is the first step towards the mass production of biologic drugs including innovative products and biosimilars. The plant will simultaneously be certified in the USA to meet the FDA and GMP requirements and will be the first of its kind production in Russia. Through this project the company will be able to deliver innovative medicines for the treatment of many socially significant diseases. As part of the investment agreement, Xcellerex will provide training to R-Pharm specialists in order to ensure the most rapid and effective transfer of technology and knowledge in accordance with GMP production standards and the requirements of international regulatory bodies.

R-Pharm specializes in the supply of high-tech medicinal products and laboratory equipment for the leading federal medical research centers, hospitals and clinical hospitals, as well as the largest regional curative and preventive care institutions of the Russian Federation.

The company’s portfolio includes medicinal products of various pharmaceutical groups, including oncology, hematology, cardiology, immunology, antibacterial, anti-viral, including the treatment of HIV-infection, medicinal products used in organ transplantation, treatment of disseminated sclerosis, hemophilia and diabetes, as well as neuromuscular relaxants, radiopaque contrast agents and drugs for anesthesia.

The company’s core businesses are manufacturing of finished dosage forms, active pharmaceutical ingredients of chemical nature and biotech substances; research and development of innovative products and technologies; bringing the highly efficient pharmaceutical products to the Russian market; as well as implementation of education and training programs for pharmaceutical and healthcare industries.

R-Pharm completes the deal to sell a 10% stake to Mitsui

pharma-deal
October 17 marked the closing of a deal on acquisition of a 10% stake in R-Pharm, a Russian pharmaceutical company, by Mitsui & Co., Ltd.

R-Pharm becomes the first Russian company to conduct clinical trials in South Korea

laboratory
A meeting with the doctors and employees of 8 leading South Korean clinical and university centers was held in Seoul.

A fund established by RDIF and JBIC invests in R-Pharm

dmitriev
The first deal of the joint investment fund established by Japan Bank for International Cooperation and Russian Direct Investment Fund will be investment in R-Pharm

R-Pharm will help to introduce innovative diagnostic methods in Kazakhstan

deal
On August 26, during the Eurasian Week held in Astana, ULNANOTECH, LLP R-Pharm Kazakhstan and LLC TestGen signed a cooperation agreement.

Phase III clinical study of Remimazolam starts in Russia

research
R-Pharm began the Phase III clinical study of the medicine used to induce and maintain the general anesthesia

Otsuka and R-Pharm sign a licensing agreement to market Deltyba

deal
Otsuka Pharmaceutical Co. Ltd. and R-Pharm Group signed a licensing agreement to manufacture and market Deltyba

R-Pharm and Aspyrian Therapeutics signed an exclusive licensing agreement

research
R-Pharm Overseas, Inc., a division of R-Pharm Group, signed an exclusive licensing agreement with Aspyrian Therapeutics Inc.

MSD and R-Pharm invested 200 million rubles in the localization of Raltegravir

r-pharm
MSD, an international biopharmaceutical company, and R-Pharm, a leading Russian pharmaceutical company, have announced the successful completion of their joint project

R-Pharm plans to launch its products onto the Japanese market

repik
In three years, the Russian pharmaceutical company R-Pharm intends to launch some of its medicines onto the Japanese market.

R-Pharm and Nacimbio established a joint venture

r-pharm-nacimbio
National Immunobiological Company, a part of Rostec Corporation, and R-Pharm, a Russian pharmaceutical company, signed an agreement to establish a joint venture.

New product of R-Pharm will reduce the cost of HCV treatment

r-pharm
On April 25, Vladimir Putin met the representatives of businesses in the Yaroslavl region. The event was attended by Vasily Ignatiev, the CEO of R-Pharm Group. The CEO of R-Pharm mentioned the suppor...

R-Pharm releases first batch of medicines with protective labeling

labelling
On March 14, ORTAT, a pharmaceutical plant of R-Pharm Group, released the first batch of Herceptin, a medicine, with DataMatrix code. 2D code on the package of the medicinal product fully complies wit...

R-Pharm and FUJIFILM Corporation Sign Agreement on Comprehensive Cooperation in the Field of Healthc...

R-Pharm group and FUJIFILM Corporation signed an agreement on healthcare cooperation on the sidelines of the Russian-Japanese dialogue within the visit of the President of the Russian Federation V.V. ...

The first Immuno-Oncology Drug of the Innovative PD-1 Inhibitor Class has been Approved in Russia

MSD, known as Merck & Co. in the United States and Canada, informs that the first-in-class of the PD-1 inhibitors immuno-oncology drug, pembrolizumab, has been approved in Russia. This drug is ind...

R-Pharm took part at WorldSkills Hi-Tech National Championship

Young Professionals of R-Pharm Perform at WorldSkills Hi-Tech National Championship
Championship III in cross-industry blue-collar jobs of hi-tech section took place in Yekaterinburg from October 30th to November 3d. R-Pharm group acted as the organizer of the competence “Laboratory ...

R-Pharm Rolls Out Arlansa for Treatment of Chronic Viral Hepatitis C

R-Pharm Group Rolls Out New Drug Arlansa (Narlaprevir)
A new direct acting antiviral drug Arlansa (Narlaprevir) for therapy of VHC was introduced within All-Russian research and practice conference III with international engagement “Socially significant a...